D. Jeffrey Keyser - 09 Jan 2026 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Director
Signature
/s/ D. Jeffrey Keyser
Issuer symbol
LTRN
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
13 Jan 2026, 16:05:14 UTC
Previous filing
23 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KEYSER D JEFFREY Director 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS /s/ D. Jeffrey Keyser 12 Jan 2026 0001393516

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 09 Jan 2026 Common Stock 25,000 $3.49 Direct F1
transaction LTRN Stock Option (Right to Buy) Award $0 +28,844 $0.000000 28,844 09 Jan 2026 Common Stock 28,844 $3.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.
F2 The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.